Cell Systems

Executive Summary

Cell Systems is a privately held company headquartered in Cambridge, Massachusetts, specializing in the production of primary human cells, cell culture media, and reagents for biomedical research. Founded in 2018, the company operates at the intersection of cell therapy and regenerative medicine, offering tools that enhance reproducibility and biological relevance in 2D and 3D culture, organ-on-a-chip platforms, and microfluidic devices. By providing high-quality endothelial cells and optimized media, Cell Systems addresses a critical need for consistent and physiologically relevant in vitro models, supporting advances in drug discovery, toxicology, and tissue engineering. The company's products are designed to reduce variability and improve experimental outcomes, making them essential for academic and pharmaceutical R&D. With a focus on primary cell systems, Cell Systems positions itself as a key enabler in the growing market for advanced cell culture technologies.

Upcoming Catalysts (preview)

• Q2 2026Launch of new primary cell types for organ-on-a-chip applications70% success
• Q3 2026Strategic partnership with a major organ-on-a-chip or microfluidics company50% success
• H2 2026Series A funding round to expand manufacturing capacity60% success